Skip to main content

Company

BrainStorm Cell Therapeutics Inc.

NASDAQ:BCLI

BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.

3 stories

Pharma & Biotech

BrainStorm shares plunge 56% after FDA advisors reject ALS cell therapy

By Proactive 28/09/2023

Pharma & Biotech

BrainStorm Cell plummets after FDA raises doubts over ALS therapy

By Proactive 25/09/2023

Pharma & Biotech

Maxim Group says BrainStorm Cell Therapeutics now has sufficient cash to fund key phase 3 trial of NurOwn

NurOwn has been administered to 75 patients with amyotrophic lateral sclerosis (ALS) in clinical trials in the U.S and Israel

By Proactive 08/06/2018